Ribeiro Ramiro sold $73K of EYPT

Ribeiro Ramiro (Chief Medical Officer) sold 4,875 shares of EyePoint, Inc. (EYPT) at an average of $15.01 ($15.00–$15.02) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ribeiro Ramiro
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EYPT
Neutral
high confidence
Mentioned
$EYPT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EYPTNeutralLow
01

Why it matters

The newest fact is the CMO’s open-market sale details and post-transaction holdings (0 shares), but it does not include any new EyePoint business update.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure reduces the likelihood of a fundamental signal.

03

What to watch

The filing does not disclose reasons for the sale beyond the pre-arranged plan, and the transaction size is not described as unusually large relative to typical insider activity.

Relevance 2/10Novelty 3/10Timing: filed July 2, covering June 30 sales

Background

The article is a SEC Form 4 insider transaction disclosure for EyePoint, Inc. (EYPT).

Company-level read

Ticker impact

$EYPTNeutralHigh confidence
Context

EyePoint disclosed a Form 4 showing CMO Ribeiro Ramiro sold 4,875 shares at about $15.01, leaving 0 shares after the sale.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically muted for 10b5-1 sales.

Evidence & confidence

The filing is a routine insider transaction, explicitly pre-arranged via a Rule 10b5-1 plan, and provides no new company-specific fundamentals or guidance.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be misread as bearish; a 10b5-1 plan often reflects liquidity planning rather than negative expectations.

Key entities

  • EyePoint, Inc.

    Company that filed the Form 4 disclosing the insider sale.

  • Ribeiro Ramiro

    Chief Medical Officer who sold shares under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EYPTHighAI 8/10

EyePoint Pharma Earnings Call: DME Focus After Wet AMD Setback

EyePoint Pharma reported Q3 earnings, highlighting a setback in wet AMD trials and a 53% workforce reduction. Despite this, the company remains focused on DURAVYU for diabetic macular edema (DME), citing positive VERONA study results. EyePoint has $118M in cash, expected to last into late Q3 2027, and plans to report DME trial results in early Q4 2027.

$EYPTHighAI 8/10

Stifel cuts EyePoint stock price target on trial setbacks

Stifel reduced its price target for EyePoint Inc. (EYPT) to $5.00 from $6.00, citing clinical trial setbacks. The company's stock is near its 52-week low, down 97% over the past year. EyePoint reported a larger-than-expected loss but exceeded revenue expectations in Q3 2026. The company has $118 million in cash and is focusing on its Duravyu treatment for diabetic macular edema.

$EYPTMed

EyePoint Misses As Twin Wet AMD Failures Leave A Shrunken Company Racing Its Cash Runway To A Binary DME Readout

EyePoint reported a Q3 loss of $1.07 per share, missing estimates, with revenue of $0.76M. The company halted its wet AMD program after trial failures, focusing on DME. Cash reserves fell to $118M, and the company plans workforce reductions. DME trial results are expected in Q4 2027, but financing may be needed before then. Shares have dropped 97% since August.

$EYPTMedAI 8/10

EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments

EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the posit